On November 30, 2020 Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, reported the formation of a new spin out, SynOx Therapeutics, as a vehicle for the continued development of emactuzumab as an effective treatment for tenosynovial giant cell tumours (Press release, Celleron, NOV 30, 2020, View Source [SID1234571942]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Celleron established SynOx Therapeutics to complete clinical development and obtain marketing approval for emactuzumab. SynOx Therapeutics has attracted €37M venture funding co-led by life science investors HealthCap and Medicxi, joined by Forbion and Gimv. The investment allows SynOx to complete the development of emactuzumab for the treatment of diffuse tenosynovial giant cell tumours (dTGCT).
Emactuzumab is a clinical-stage humanised CSF-1R targeted antibody designed to deplete macrophages in tumour tissue. It has shown a favourable safety profile in patients and encouraging efficacy for TGCT, a rare disease characterised by the proliferation of macrophages in the synovial tissue of the joint and tendon sheath.
Professor Nick La Thangue, Chief Executive Officer of Celleron and SynOx commented: "We are very excited to be working on emactuzumab and feel privileged to be supported by a strong syndicate of leading investors. The successful launch of SynOx, as a single asset company with dedicated funding, reflects Celleron’s business model of spinning-out new assets and securing independent funding".
Professor David Kerr, Chief Medical Officer of Celleron and SynOx commented: "SynOx’s focus is on developing emactuzumab to provide the best possible therapeutic agent for patients suffering from TGCT, which remains a very debilitating disease with limited clinical options. I am sure that our deep understanding of emactuzumab’s mechanism of action will yield other tractable disease targets"